Document Type
Article
Publication Date
11-22-2016
Abstract
Derivatives of dasatinib were synthesized via esterification with 25 carboxylic acids including amino acids and fatty acids by extending the inhibitor to interact with more diverse sites and to improve specificity. Dasatinib-L-arginine derivative (Das-R, 7) was the most potent of the inhibitors tested with IC50 values of 4.4 nM, <0.25 nM, and <0.45 nM against Csk, Src, and Abl kinases, respectively. The highest selectivity ratio obtained in our study, 91.4 Csk/Src belonged to compound 18 (Das-C10) with an IC50 of 3.2 μM for Csk compared to 35 nM for Src. Furthermore, many compounds displayed increased selectivity toward Src, as compared with Abl. Compounds 15 (Das-E) and 13 (Das-C) demonstrated the largest gains (10.2 and 10.3 Abl/Src IC50 ratios). Das-R (IC50 = 2.06 μM) was significantly more potent than Das (IC50 = 26.3 μM) against Panc-1 cells while they both showed an IC50 < 51.2 pM against BV-173 and K562 cells. Molecular modeling and binding free energy simulations revealed a good agreement with the experimental results and rationalized differences in selectivity of the studied compounds. Integration of experimental and computational approaches in the design and biochemical screening of dasatinib derivatives facilitated rational engineering and diversification of dasatinib scaffold, providing useful insights into mechanisms of kinase selectivity.
Recommended Citation
Tiwari, R. K., Brown, A., Shirazi, A. N., Bolton, J., Tse, A., Verkhivker, G., Parang, K. and Sun, G. (2016), Design, Synthesis, and Evaluation of Dasatinib-Amino Acid and Dasatinib-Fatty Acid Conjugates as Protein Tyrosine Kinase Inhibitors. ChemMedChem. Accepted Author Manuscript. doi:10.1002/cmdc.201600387
Copyright
Wiley/ChemPubSoc Europe
Included in
Enzymes and Coenzymes Commons, Medicinal-Pharmaceutical Chemistry Commons, Pharmaceutical Preparations Commons, Pharmacy and Pharmaceutical Sciences Commons
Comments
This is the accepted version of the following article:
Tiwari, R. K., Brown, A., Shirazi, A. N., Bolton, J., Tse, A., Verkhivker, G., Parang, K. and Sun, G. (2016), Design, Synthesis, and Evaluation of Dasatinib-Amino Acid and Dasatinib-Fatty Acid Conjugates as Protein Tyrosine Kinase Inhibitors. ChemMedChem. Accepted Author Manuscript. doi:10.1002/cmdc.201600387
which has been published in final form at DOI: 10.1002/cmdc.201600387. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.